Pfizer ( NYSE:PFE ) just gave positive signs in its recent financial guidance for full year 2025. They projected their operational revenue to grow flat 5% year-over-year from their midpoint of 2024 guidance.

And therefore, they anticipated to see their revenues between $61 to $64 billion next year. And for their adjusted diluted earnings per share (EPS), they expected growth of between 10% to 18% with EPS of $2.80 to $3.00 per share.

The drug manufacturer giant said that their guidance has taken into account the anticipated $1 billion unfavorable impact from the changes in Medicare Part D benefit under the inflation Reduction Act. Thus, Pfizer said to continue doing cost realignment and manufacturing management to achieve financial stability.

Pfizer is currently working on danuglipron in phase 2 trial, it's a weight loss drug that belongs to an oral GLP-1 receptor agonist. An oral GLP-1 receptor agonist is a medication that enhance insulin secretion to regulate blood sugar level and cravings.

The past trials result gave promise in reducing body weight but it's still too early to say it's the best weight loss drug when other GLP-1 agonists like Ozempic and Wegovy already available in the market and become popular options these days.

Deep dive into Pfizer 's performance with charts, breakdowns, insiders, politician trading activities, guru insights and more by visiting GuruFocus now!

This article first appeared on GuruFocus .